Journals | Policy | Permission

Journal of Clinical Medicine Research

Review

Volume 8, Number 1, January 2016, pages 10-14

Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering

Sodium-glucose cotransporter 2 (SGLT-2) mediates approximately 90% of active renal glucose reabsorption in the proximal tubule of the kidney [1]. Recently, the new drug for type 2 diabetes, the SGLT-2 inhibitor was developed. The SGLT-2 inhibitor is reversible inhibitor of SGLT-2, leading to reduction of renal glucose reabsorption and decrease of plasma glucose, in an insulin-independent manner [2]. Diabetes is a strong independent risk factor for cardiovascular diseases (CVDs) [3]. Compared with subjects without diabetes, the relative risk for CVD is 2 - 3 times greater in men with diabetes and 3 - 4 times greater in women with diabetes [4-10]. In addition to glucose control, the management of coronary risk factors is very important for patients with diabetes. Here we reviewed published articles about the possible anti-atherosclerotic effects beyond glucose lowering of the SGLT-2 inhibitors.

We searched by using Pubmed (Table 1), and found 770 published articles about SGLT-2 inhibitors. Ten kinds of SGLT-2 inhibitors were detected, and we searched the published articles about each SGLT-2 inhibitor. The number of published articles about dapagliflozin was the greatest among SGLT-2 inhibitors. Since SGLT-2 inhibitors have similar chemical structures, we concentrated on the published articles about dapagliflozin.

Click to view

Table 1. The Reported Sodium Glucose Cotransporter 2 Inhibitors

Dapagliflozin also reduces renal glucose reabsorption and decrease of plasma glucose, in an insulin-independent manner [2], which induces reduction of body weight and blood pressure. Reduction of body weight and blood pressure by SGLT-2 inhibitors is also induced by osmotic diuretics [11]. There were 106 published articles about “dapagliflozin and body weight” and 78 articles about “dapagliflozin and blood pressure”.

Matthaei et al studied effects of dapagliflozin 10 mg/day or placebo for 52 weeks on metabolic parameters in patients with type 2 diabetes using sulphonylurea and metformin [12], HbA1c and fasting plasma glucose levels showed greater improvement from baseline with dapagliflozin (-0.8% and -1.5 mmol/L) than with placebo. Dapagliflozin was associated with greater reductions in body weight and systolic blood pressure (-2.9 kg and -1.0 mm Hg) compared with placebo. Dapagliflozin was administered as monotherapy (n = 249) or combination therapy (n = 479) with existing antihyperglycemic agents to Japanese patients with diabetes for 52 weeks [13]. In patients receiving dapagliflozin as monotherapy or combination therapy, reductions from baseline were observed in HbA1c (-0.7% in both groups), weight (-2.6 and -2.1 kg, respectively), and systolic blood pressure (-5.2 and -3.9 mm Hg). Dapagliflozin reduced body weight and blood pressure by both monotherapy and add-on therapy.

In a meta-analysis including all trials with a duration of at least 12 weeks, comparing an SGLT-2 inhibitor with a non-SGLT-2 inhibitor agent in type 2 diabetes, SGLT-2 inhibitors are effective in the treatment of type 2 diabetes, providing additional benefits, such as weight loss, reduction of blood pressure [14].

Improvement in glucose control, body weight and blood pressure by dapagliflozin was almost confirmed by a relatively large number of studies. We hypothesized the underlying mechanisms for possible anti-atherosclerotic effects beyond glucose lowering of SGLT-2 inhibitors (Fig. 1). We searched the published articles about the effects of dapagliflozin on metabolic risk factors by using Pubmed (Table 2). In this search, we excluded “Original Articles using animals or cells”, “Narrative Reviews” and “Expert Opinions”, and we considered “Original Articles”, Systematic Reviews” and “Meta-analysis” as important information.

Click for large image

Figure 1. Possible anti-atherosclerotic effects beyond glucose lowering of sodium glucose cotransporter 2 inhibitors. HDL-C: high-density lipoprotein-cholesterol; SGLT-2: sodium glucose cotransporter 2; TG: triglyceride.

Click to view

Table 2. The Search Strategy to Find the Anti-Atherosclerotic Effects of Dapagliflozin

Patients (N = 182) were randomly assigned to receive dapagliflozin 10 mg/day or placebo added to open-label metformin [15]. Over 102 weeks, dapagliflozin-treated patients showed reductions in waist circumference by -5.0 cm and fat mass by -2.8 kg. In another study, 182 patients with diabetes were allocated to receive dapagliflozin 10 mg/day or placebo added to open-label metformin for 24 weeks [16]. Placebo-corrected changes with dapagliflozin were as follows: waist circumference, -1.52 cm (95% CI = -2.74 to -0.31; P = 0.0143); fat mass, -1.48 kg (95% CI = -2.22 to -0.74; P = 0.0001); visceral adipose tissue, -258.4 cm³ (95% CI = -448.1 to -68.6; nominal P = 0.0084).

We selected “Original Articles” which evaluated insulin sensitivity using the euglycemic hyperinsulinemic clamp. Twenty-four subjects with diabetes received dapagliflozin (n = 16) or placebo (n = 8) for 2 weeks, and the euglycemic hyperinsulinemic clamp was performed before and after treatment [17]. Dapagliflozin significantly improved whole-body insulin sensitivity. In another study, 18 diabetic men were randomized to receive either dapagliflozin (n = 12) or placebo (n = 6) for 2 weeks [18]. Improvement in muscle insulin sensitivity by dapagliflozin was observed by using the euglycemic hyperinsulinemic clamp. Forty-four subjects were randomized to receive dapagliflozin 5 mg or matching placebo once daily for 12 weeks [19]. Insulin sensitivity was assessed by measuring the glucose disappearance rate during the last 40 min of a 5-h euglycemic hyperinsulinemic clamp. Dapagliflozin treatment improved insulin sensitivity.

In the study by Matthaei et al [12], adjusted % changes of fasting LDL-cholesterol from baseline to week 52 (95% CI) in the placebo group and the dapagliflozin group were 0.9 (-6.7, 9.1) and 4.8 (-1.5, 11.5), respectively. Adjusted % changes in fasting HDL-cholesterol were 0.6 (-3.6, 4.9) and 6.9 (3.3, 10.6) in the placebo group and the dapagliflozin group, respectively. Adjusted % changes in fasting LDL/HDL ratio were 0.9 (-7.8, 10.5) and -2.5 (-9.3, 4.7). Adjusted % changes in fasting triglyceride were 2.9 (-8.1, 15.2) and -8.0 (-16.0, 0.7). This study suggested that dapagliflozin is beneficially associated with serum lipids. Matthaei et al also evaluated the efficacy and safety of a 24-week dapagliflozin treatment in patients with type 2 diabetes inadequately controlled with metformin and sulfonylurea [20]. Patients receiving dapagliflozin showed placebo-subtracted increases in total, LDL, and HDL-cholesterol (11.4 mg/dL, P = 0.0091; 11.4 mg/dL, P = 0.0030; 2.2 mg/dL, P = 0.0172, respectively) with no change in LDL/HDL ratio (0.1; P = 0.2008) or triglycerides (-16.5 mg/dL; P = 0.1755). This study did not show evident beneficial effects of dapagliflozin for serum lipids, except for an increase of HDL-cholesterol. In a meta-analysis of randomized clinical trials, SGLT-2 inhibitors determined a modest but statistically significant increase in HDL-cholesterol, with no effect on triglyceride and on total and LDL-cholesterol [14].

In the review which critically assessed the results of up-to-date clinical trials with dapagliflozin [21], it was described that high sensitivity C-reactive protein levels were decreased in dapagliflozin-treated patients. We could not find published articles about effects of dapagliflozin on adipocytokines including interleukin-6, tumor necrosis factor alpha and adiponectin.

In the study by Merovci et al [18], insulin-mediated tissue glucose disposal increased by approximately 18% after 2-week dapagliflozin treatment, while placebo-treated subjects had no change in insulin sensitivity. Following dapagliflozin treatment, an increase in fasting plasma glucagon concentration was observed. Glucagon is associated with insulin resistance [22]. An influence of increase of glucagon secretion by SGLT-2 inhibitors on insulin resistance or metabolic risk factors should be carefully observed.

SGLT-2 inhibitors seem to be associated with weight loss and reduction of blood pressure by a relatively large number of studies. However, the studies that investigated effects of dapagliflozin on visceral fat, insulin sensitivity, serum lipids, inflammation and adipocytokines are very limited. Furthermore, an influence of increase in glucagon secretion by SGLT-2 inhibitors on metabolic risk factors remains unknown. The glucose lowering effect in an insulin-independent manner of SGLT-2 inhibitors prevents hyperinsulinemia, which may also contribute to anti-atherogenesis. Very recently, Zinman et al showed that the addition of another SGLT-2 inhibitor, empagliflozin, reduced rates of death from cardiovascular causes (38% relative risk reduction), hospitalization for heart failure (35%), and death from any cause (32%) [23], suggesting a possible anti-atherosclerotic effect of SGLT-2 inhibitors. However, further studies should be performed to elucidate anti-atherosclerotic effect of SGLT-2 inhibitors.

Competing Interests

The authors declare that they have no competing interests.

Funding

This work was funded by a grant from the National Center for Global Health and Medicine (26-112).

1. Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, Koepsell H, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011;22(1):104-112.
   doi pubmed
2. Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract. 2008;62(8):1279-1284.
   doi pubmed
3. Savage PJ. Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention. Ann Intern Med. 1996;124(1 Pt 2):123-126.
   doi pubmed
4. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434-444.
   doi pubmed
5. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241(19):2035-2038.
   doi
6. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. Br Med J (Clin Res Ed). 1983;287(6396):867-870.
   doi
7. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA. 1991;265(5):627-631.
   doi pubmed
8. Goldbourt U, Yaari S, Medalie JH. Factors predictive of long-term coronary heart disease mortality among 10,059 male Israeli civil servants and municipal employees. A 23-year mortality follow-up in the Israeli Ischemic Heart Disease Study. Cardiology. 1993;82(2-3):100-121.
   doi pubmed
9. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, Arky RA, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med. 1991;151(6):1141-1147.
   doi pubmed
10. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229-234.
    doi pubmed
11. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014;8(5):330-339.
    doi pubmed
12. Matthaei S, Bowering K, Rohwedder K, Sugg J, Parikh S, Johnsson E. Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes. Diabetes Obes Metab. 2015;17(11):1075-1084.
    doi pubmed
13. Kaku K, Maegawa H, Tanizawa Y, Kiyosue A, Ide Y, Tokudome T, Hoshino Y, et al. Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study. Diabetes Ther. 2014;5(2):415-433.
    doi pubmed
14. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16(5):457-466.
    doi pubmed
15. Bolinder J, Ljunggren O, Johansson L, Wilding J, Langkilde AM, Sjostrom CD, Sugg J, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16(2):159-169.
    doi pubmed
16. Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020-1031.
    doi pubmed
17. Merovci A, Mari A, Solis C, Xiong J, Daniele G, Chavez-Velazquez A, Tripathy D, et al. Dapagliflozin lowers plasma glucose concentration and improves beta-cell function. J Clin Endocrinol Metab. 2015;100(5):1927-1932.
    doi pubmed
18. Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, Xiong J, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124(2):509-514.
    doi pubmed
19. Mudaliar S, Henry RR, Boden G, Smith S, Chalamandaris AG, Duchesne D, Iqbal N, et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther. 2014;16(3):137-144.
    doi pubmed
20. Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care. 2015;38(3):365-372.
    doi pubmed
21. Katsiki N, Papanas N, Mikhailidis DP. Dapagliflozin: more than just another oral glucose-lowering agent? Expert Opin Investig Drugs. 2010;19(12):1581-1589.
    doi pubmed
22. Eaton RP. Evolving role of glucagon in human diabetes mellitus. Diabetes. 1975;24(5):523-524.
    doi pubmed
23. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015.
    doi pubmed

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Journal of Clinical Medicine Research is published by Elmer Press Inc.